The pharmacotherapy of Takayasu arteritis (TAK) with disease-modifying anti-rheumatic
drugs (DMARDs) is an evolving area. A systematic review of Scopus, Web of Science …

We evaluated clinical response, normalization of inflammatory markers, angiographic
stabilization (primary outcomes), relapses and adverse events (secondary outcomes) in …

To clarify the risk of tuberculosis (TB) infection in patients with Takayasu arteritis (TAK). In
this study, we conducted a comprehensive search across multiple databases, including …

Takayasu arteritis (TAK) is a rare granulomatous vasculitis of unknown etiology that mainly
affects the aorta and its major branches. The aim is to describe the clinical features …

Objectives Large vessel vasculitis (LVV) is characterised by a high relapse rate. Because
accurate assessment of the LVV disease status can be difficult, an accurate prognostic …

Pediatric rheumatologists take care of multisystem autoimmune disease in children.
Musculoskeletal diseases such as juvenile idiopathic arthritis (JIA) and childhood a Red …

Dysbiosis and reduced microbial diversity has been identified in patients with small, medium
and large vessel vasculitis. Although limited data suggests microbiomes may …

As a common treatment for rheumatoid arthritis (RA), the adverse reactions of TNF-α
inhibitors (TNFis) in practical application have garnered attention. This study aims to …

Takayasu arteritis (TAK) is a rare systemic vasculitis primarily affecting the aorta and its
major branches. Early diagnosis is critical to prevent severe vascular complications, yet …

Background Takayasu arteritis is a rare and chronic granulomatous vasculitis that affects the
large vessels. Takayasu arteritis targets the aorta and its branches and is still of unknown …